Summary Organ transplant recipients receiving immunosuppression show a dramatically increased risk of non-melanoma skin cancer. The cause of this increase is not known. We report that the rate of loss of heterozygosity (at all the loci we examined) was significantly lower in tumours from immunosuppressed individuals than in tumours from immunocompetent subjects [20 out of 148 (14%) vs 157 out of 428 (37%); P < 0.0001]. These results suggest that tumours in immunosuppressed individuals have a different molecular pathogenesis.
Patients receiving immunosuppressive therapy after organ transplantation show up to a 250-fold increase in the incidence of nonmelanoma skin cancers (NMSCs) and their precursor lesions (Abel, 1989; Hartevelt et al, 1990; Espana et al, 1995; Glover et al, 1997) . In such patients the high prevalence of infection by a spectrum of human papilloma virus (HPV) types together with a high incidence of other neoplasms associated with a viral pathogenesis has suggested a role for virus during NMSC development (Barr et al, 1989) . However, in skin, unlike cervical carcinoma, compelling evidence that HPVs play a causative role, rather than being mere passengers, is lacking. It is also possible that other viruses such as the recently described Kaposi's sarcoma herpes-like virus (KSHV) (Boshoff et al, 1996) or as yet unidentified viruses may be important. We therefore sought indirect evidence for a different molecular pathogenesis in these tumours that would provide support for a causal role for one or more types of virus, including viruses that had not yet been identified.
Tumour-suppressor gene inactivation commonly occurs by mutation of one allele accompanied by chromosome loss of the wild-type allele (Knudson, 1991) . Other mechanisms of tumoursuppressor gene activation can occur, including binding of the products of virally encoded oncogenes or changes in methylation status of tumour-suppressor genes (Vousden, 1993; Kinzler and Vogelstein, 1996) . If, in tumours from immunosuppressed individuals, tumour-suppressor genes are being inactivated by alternative means, then the rate or pattern of loss of heterozygosity might be expected to differ from those in immunocompetent individuals. We examined this hypothesis. Ten-micrometre tissue sections were carefully microdissected to separate tumour from adjacent normal epithelium, and the DNA was extracted using phenol-chloroform (Jackson et al, 1995) . In all cases, control DNA from either adjacent normal skin or blood was used. Tumour and control DNA was subject to polymerase chain reaction (PCR) amplification using one [y-32P]ATP (Life Sciences, Amersham, UK) end-labelled primer as previously described (Rehman et al, 1996) , using microsatellite markers 3p (D3S1293), 9p (D9S162, D9S171), 9q (D9S197), 13q (D13S170), 17p (D17S796) and 17q (D17S785) (Research Genetics, Huntsville, AL, USA). PCR products were resolved on a 6% polyacrylamide gel and then fixed and dried; the bands were visualized by autoradiography and the LOH was scored by eye.
Statistical comparisons were made using the X2 test and Fisher's exact test.
RESULTS
The overall LOH for the six loci examined was significantly lower in tumours from transplant individuals than in control tumours [LOH in 20 out of 148 (14%) vs 157 out of 428 (37%), P < 0.0001] (see Table 1 ). Examination of the pattern of loss by chromosome arm shows that the differences were particularly marked for 3p and 13q as well as for 17p and 17q. Examples of allelic loss are shown in Figure 1 . The difference between the patient groups was evident for both invasive and in situ lesions (transplant SCC vs control SCC, P = 0.002; transplant in situ lesions vs control in situ lesions, P = 0.008). (1993) showed that the rate of LOH in cervical carcinoma (in which there is thought to be a viral pathogenesis) was lower than in some other solid tumours. Interpretation of these results is however difflcult as comparisons were made between tumours from different organs. Similarly, rates of p53 mutation have been reported to be low in cervical cancers in which HPV was detected (compared with tumours in which virus was not detected) in some, but not all, studies of cervical carcinoma, the implication being that viral products may inactivate the p53 tumour-suppressor genes by alternative mechanisms to mutation (Crook et al, 1991; Busby-Earle et al, 1992; Vousden, 1993) . Transplant recipients receiving immunosuppression show an elevated risk of various tumour types that have in common a possible viral pathogenesis, including lymphoma, cervix and Kaposi's sarcoma of the skin (Kinlen et al, 1979; London et al 1995) . Given the increased risk of NMSC and the high prevalence of HPV infection, it is therefore tempting to imagine that HPV cause NMSC. However, unlike the situation in cervix, a (Vousden, 1993) . Other non-HPV viruses could also be aetiologically important.
Resolving this question is difficult because of the large number of human papillomaviruses, ignorance of their potential pathogenic mechanisms and the problem of providing evidence for other as yet uncharacterized viruses (Stark et al, 1994; Tieben et al, 1994) . The results presented, while compatible with a role for viral pathogenesis, are puzzling in at least one respect. If only one particular tumour-suppressor gene was involved, then one would imagine that a particular viral product would interact with this pathway, and one would not expect to see a difference in LOH at all the loci examined. On the contrary, the finding of differences at multiple loci suggests that if the explanation lies with a putative virus, then this virus is capable of inactivating several tumoursuppressor genes. Alternatively, and perhaps more interestingly, tumours in immunosuppressed individuals in which there may be decreased immunosurveillance may be able to bypass the need to inactivate certain tumour-suppressor genes.
